Roche Holding said it agreed to buy 89bio for up to $3.5 billion, seeking to bolster its drug pipeline by adding an ...

Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments ...

Roche Holding AG agreed to buy biopharmaceutical company 89bio Inc. for as much as $3.5 billion, another acquisition to ...

Roche has signed a definitive merger agreement for the acquisition of clinical-stage biopharmaceutical company 89bio, for a ...

Roche is acquiring 89bio for $2.4 billion plus potential milestone payouts, bolstering its pipeline with late-stage MASH drug ...

Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesityAcquisition ...

Roche is buying 89bio, the maker of an experimental drug for a liver disease that’s attracted major pharma interest, in a ...

The star of the acquisition, which includes a contingent value right of $6 per share, is pegozafermin, an FGF21 analog in ...

The $14.50-per-share deal equates to a purchase price of $2.4 billion at closing, with Roche dangling another $6 per share in ...

Roche has agreed to buy drugmaker 89bio in a deal worth up to $3.5bn, the first US acquisition by a Swiss pharmaceuticals group since the Trump administration hit the country with the highest tariffs ...

Basel: Roche has announced that it has entered into a definitive merger agreement to acquire 89bio, Inc., a publicly listed ...

Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities ...